tiprankstipranks
Astria Therapeutics gets ODD from FDA for navenibar to treat HAE
PremiumThe FlyAstria Therapeutics gets ODD from FDA for navenibar to treat HAE
2M ago
Astria Therapeutics price target raised to $26 from $25 at Oppenheimer
Premium
The Fly
Astria Therapeutics price target raised to $26 from $25 at Oppenheimer
3M ago
Astria Therapeutics reports Q2 EPS (43c), consensus (38c)
Premium
The Fly
Astria Therapeutics reports Q2 EPS (43c), consensus (38c)
3M ago
Astria Therapeutics price target lowered to $25 from $29 at Oppenheimer
PremiumThe FlyAstria Therapeutics price target lowered to $25 from $29 at Oppenheimer
6M ago
Astria Therapeutics reports Q1 EPS (38c), consensus (36c)
Premium
The Fly
Astria Therapeutics reports Q1 EPS (38c), consensus (36c)
7M ago
Astria Therapeutics price target lowered to $16 from $18 at H.C. Wainwright
Premium
The Fly
Astria Therapeutics price target lowered to $16 from $18 at H.C. Wainwright
7M ago
Astria: ‘Positive’ initial proof-of-concept results from STAR-0215 for HAE trial
PremiumThe FlyAstria: ‘Positive’ initial proof-of-concept results from STAR-0215 for HAE trial
8M ago
Astria Therapeutics, Inc. Is Worried About This – Should You Be Worried Too?
Premium
Company Announcements
Astria Therapeutics, Inc. Is Worried About This – Should You Be Worried Too?
9M ago
Astria Therapeutics reports Q4 EPS (86c), consensus (78c)
Premium
The Fly
Astria Therapeutics reports Q4 EPS (86c), consensus (78c)
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100